Single Chain Antibody Patents (Class 424/135.1)
-
Patent number: 8962806Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.Type: GrantFiled: December 29, 2008Date of Patent: February 24, 2015Assignees: Dana-Farber Cancer Institute, Inc., The Bingham and Women's HospitalInventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
-
Patent number: 8962805Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: March 21, 2014Date of Patent: February 24, 2015Assignee: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Publication number: 20150050280Abstract: Methods of using M-CSF antibodies to treat macrophage-associated diseases including atherosclerosis and HIV are provided.Type: ApplicationFiled: June 20, 2014Publication date: February 19, 2015Inventor: William M. Kavanaugh
-
Publication number: 20150050281Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: ApplicationFiled: September 9, 2014Publication date: February 19, 2015Inventors: Irene GRISWOLD-PRENNER, Nancy E. STAGLIANO, Vu Cao DANG
-
Publication number: 20150044213Abstract: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.Type: ApplicationFiled: August 18, 2014Publication date: February 12, 2015Inventors: Lutz Asmus, Michael Möller, Robert Gurny, John P.A. Grimshaw
-
Publication number: 20150044212Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.Type: ApplicationFiled: August 7, 2014Publication date: February 12, 2015Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
-
Publication number: 20150037336Abstract: The present application relates to the combined use of an antigen-binding protein that binds HB-EGF and an EGFR tyrosine kinase inhibitor in medical treatment.Type: ApplicationFiled: February 20, 2013Publication date: February 5, 2015Applicant: U3 PHARMA GMBHInventor: Esther Zwick Wallasch
-
Patent number: 8945570Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.Type: GrantFiled: October 26, 2012Date of Patent: February 3, 2015Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
-
Patent number: 8940299Abstract: A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell.Type: GrantFiled: March 2, 2009Date of Patent: January 27, 2015Assignee: Case Western Reserve UniversityInventors: M. Edward Medof, Michael G. Strainic, Young A Choi
-
Patent number: 8940874Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: GrantFiled: November 30, 2012Date of Patent: January 27, 2015Assignees: Wyeth LLC, MedImmune LimitedInventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
-
Publication number: 20150023964Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than the antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: ApplicationFiled: July 15, 2014Publication date: January 22, 2015Applicant: MACROGENICS, INC.Inventors: Leslie S. Johnson, Ling Huang, Robyn Gerena
-
Publication number: 20150023963Abstract: The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties.Type: ApplicationFiled: June 20, 2014Publication date: January 22, 2015Applicant: Ablynx N.V.Inventors: Hilde Stals, Veronique De Brabandere, Peter Schotte
-
Publication number: 20150017167Abstract: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: ApplicationFiled: September 18, 2014Publication date: January 15, 2015Inventors: Naoki NISHIGUCHI, Akiyoshi HIRAYAMA, Masahiro FURUTANI, Tatsuo SHIMIZU, Kiyoshi TAKAYAMA, Tomoko SHIMIZU, Kazuya SUZUKI
-
Publication number: 20150017165Abstract: Monoclonal antibodies against LRP6 and that block the Wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed.Type: ApplicationFiled: June 9, 2014Publication date: January 15, 2015Inventors: Jian-xing Ma, Kyungwon Lee, Ying Chen
-
Publication number: 20150017166Abstract: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.Type: ApplicationFiled: July 3, 2014Publication date: January 15, 2015Inventors: Brian BAKER, Jeffrey T.L. SMITH, John A. LATHAM
-
Patent number: 8932593Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.Type: GrantFiled: March 14, 2012Date of Patent: January 13, 2015Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20150010560Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.Type: ApplicationFiled: June 13, 2014Publication date: January 8, 2015Inventors: Cen XU, Agnes Eva HAMBURGER
-
Publication number: 20150010559Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.Type: ApplicationFiled: May 15, 2014Publication date: January 8, 2015Applicant: NovImmune S.A.Inventors: Marie Kosco-Vilbois, Katrien L. De Graaf, Thierry Berney, Santa Giovannoni, Domenic Bosco
-
Publication number: 20150010564Abstract: Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.Type: ApplicationFiled: August 19, 2014Publication date: January 8, 2015Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig, Lou Vaickus
-
Publication number: 20150010562Abstract: The disclosure relates to agents that inhibit the activity of Tumour Necrosis Factor Apoptosis-Inducing Ligand [TRAIL] and their use in the treatment of pulmonary hypertension.Type: ApplicationFiled: October 23, 2012Publication date: January 8, 2015Applicant: PH TherapeuticsInventor: Allan Lawrie
-
Publication number: 20150010563Abstract: Provided herein are methods for reducing corneal inflammation, reducing inflammatory cell (e.g., dendritic cell) recruitment to the cornea, and treating an corneal inflammatory disorder in a subject that include administering to the subject one or more of a MadC AM-1 antagonist, an ?4?7 integrin antagonist, a L-selectin antagonist, and an E-selectin antagonist. Also provided are compositions containing one or more of a MadC AM-1 antagonist, an ?4?7 integrin antagonist, a L-selectin antagonist, and an E-selectin antagonist, and kits containing these compositions.Type: ApplicationFiled: February 21, 2013Publication date: January 8, 2015Applicant: Massachusetts Eye & Ear InfirmaryInventors: Pedram Hamrah, Ulrich von Andrian, Aslihan Turhan
-
Publication number: 20150010561Abstract: Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule.Type: ApplicationFiled: July 9, 2014Publication date: January 8, 2015Inventors: Christopher J. Ong, Martin E. Gleave, Norihiro Hayashi, James Peacock
-
Publication number: 20150010558Abstract: Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis.Type: ApplicationFiled: February 11, 2014Publication date: January 8, 2015Applicant: GENENTECH, INC.Inventors: Jin-An JIAO, Hing C. WONG, Jack O. EGAN
-
Publication number: 20150004164Abstract: The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.Type: ApplicationFiled: December 14, 2012Publication date: January 1, 2015Inventors: Fulvio D'Acquisto, Mauro Perretti
-
Publication number: 20150004165Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: ApplicationFiled: September 8, 2014Publication date: January 1, 2015Applicant: INCYTE CORPORATIONInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J.A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
-
Publication number: 20150004163Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.Type: ApplicationFiled: July 7, 2014Publication date: January 1, 2015Inventors: Cory AHONEN, Randolph NOELLE
-
Patent number: 8920798Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: November 20, 2012Date of Patent: December 30, 2014Assignee: Amgen Inc.Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
-
Patent number: 8920776Abstract: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of variety of leukemias and lymphomas.Type: GrantFiled: January 22, 2003Date of Patent: December 30, 2014Assignee: Corixa CorporationInventors: Alexander Gaiger, Paul A. Algate, Jane Mannion, Jonathan David Clapper, Aijun Wang, Nadia Ordonez, Lauren Carter, Patricia Dianne McNeill
-
Publication number: 20140377266Abstract: Embodiments methods and compositions involving inhibitors of the immunoreceptor Natural Killer Group 2, Member D, (NKG2D) for inhibiting tumor progression and treating cancer.Type: ApplicationFiled: September 7, 2012Publication date: December 25, 2014Applicant: FRED HUTCHINSON CANCER RESEARCH CENTERInventors: Thomas Spies, Veronika Spies
-
Publication number: 20140377267Abstract: The invention relates to antibodies that bind cross-linked amyloid ? oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.Type: ApplicationFiled: August 6, 2014Publication date: December 25, 2014Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Robert Moir, Rudolph E. Tanzi
-
Publication number: 20140377265Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.Type: ApplicationFiled: July 22, 2014Publication date: December 25, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
-
Publication number: 20140370016Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: July 31, 2014Publication date: December 18, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20140370015Abstract: Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.Type: ApplicationFiled: June 17, 2014Publication date: December 18, 2014Applicant: National Cheng Kung UniversityInventors: Ming-Shi Chang, I-Ming Jou
-
Publication number: 20140370014Abstract: Alleviating obesity in a subject (e.g., a human subject) having, being suspected of having, or at risk for obesity using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.Type: ApplicationFiled: June 17, 2014Publication date: December 18, 2014Applicant: National Cheng Kung UniversityInventors: Ming-Shi Chang, Yu-Hsiang Hsu
-
Publication number: 20140370017Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.Type: ApplicationFiled: August 22, 2014Publication date: December 18, 2014Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
-
Publication number: 20140370013Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.Type: ApplicationFiled: January 14, 2014Publication date: December 18, 2014Applicant: Xencor, Inc.Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
-
Patent number: 8911728Abstract: The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also are provided.Type: GrantFiled: May 20, 2011Date of Patent: December 16, 2014Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen
-
Publication number: 20140363493Abstract: The present invention addresses a need for improved vehicles for delivering small interfering RNAs (siRNAs).Type: ApplicationFiled: June 9, 2014Publication date: December 11, 2014Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITYInventors: Deborah Palliser, Joseph Katakowski, Matthew Levy, Teresa DiLorenzo
-
Publication number: 20140356363Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: May 31, 2014Publication date: December 4, 2014Applicant: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
-
Patent number: 8900579Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: January 7, 2014Date of Patent: December 2, 2014Assignee: Alethia Biotherapuetics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Publication number: 20140348830Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.Type: ApplicationFiled: April 23, 2014Publication date: November 27, 2014Applicant: Ablynx N.V.Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
-
Publication number: 20140348829Abstract: Provided are felinized antibodies and methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one felinized antibody or fragment thereof that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.Type: ApplicationFiled: April 8, 2014Publication date: November 27, 2014Applicant: CYTODYN INC.Inventor: Richard Trauger
-
Publication number: 20140348831Abstract: Disclosed herein are antibodies that detect a lipid-like antigen on prostate cancer cells and methods of detecting and treating prostate cancer using the same.Type: ApplicationFiled: June 4, 2014Publication date: November 27, 2014Inventors: Mark I. Greene, Hongtao Zhang, Geng Zhang
-
Patent number: 8895007Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: December 7, 2011Date of Patent: November 25, 2014Assignee: Affitech Research ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
-
Patent number: 8895008Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: May 10, 2013Date of Patent: November 25, 2014Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20140341802Abstract: Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: Woomera TherapeuticsInventors: William G. North, Roy H.L. Pang
-
Publication number: 20140341901Abstract: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.Type: ApplicationFiled: January 24, 2014Publication date: November 20, 2014Applicant: NOVARTIS AGInventors: Janine R. SHULOK, Feng CONG, Mark C. FISHMAN, Seth ETTENBERG, Michael BARDROFF, Mariel DONZEAU, Stefanie URLINGER
-
Publication number: 20140341902Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.Type: ApplicationFiled: August 1, 2012Publication date: November 20, 2014Applicant: Genentech, Inc.Inventors: Heather Maecker, Bryan Irving
-
Publication number: 20140341905Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20140341903Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.Type: ApplicationFiled: October 1, 2012Publication date: November 20, 2014Applicant: Ablynx N.V.Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer